No­vo Nordisk un­veils $165M buy­out bid for a drug de­liv­ery part­ner on smart in­sulin pens

No­vo Nordisk put in an of­fer to buy out a French med­ical de­vice com­pa­ny with which it has part­nered to de­vel­op new in­jec­tion de­vices in a deal that brings a siz­able drug de­liv­ery group in­to its fold.

At €35 (about $37.00) per share, No­vo Nordisk’s pro­posed deal would val­ue Bio­corp at about €154.4 mil­lion ($165 mil­lion) — a small amount when jux­ta­posed with the large mar­ket for di­a­betes and oth­er chron­ic dis­eases that No­vo be­lieves Bio­corp’s tech­nol­o­gy can help re­shape.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER